Anti-Rheumatic Rx
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis,…
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones…
1 year 11 months ago
Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated.
@RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9
1 year 11 months ago
Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to etanercept and certolizumab showed an adjusted hazard ratio for serious infections of 1.20 (CI 0.54, 2.64).
@RheumNow #EULAR2022 ABST#OP0130
1 year 11 months ago
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Podcasts
Don't You Know Who I Am (5.17.2024)-
My Cancelled Lecture (5.11.2024)
Roadblocks to reaching remission in lupus Sponsored by GSK US Medical Affairs
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1601919334745-0'); });
Poster Hall